Search for content, post, videos
Advertisement

Elypta appoints new member to its Board of Directors

The company has announced the appointment of Eva Pisa to its Board of Directors.

“I am pleased that Dr Eva Pisa has decided to join the board of Elypta. With her background and experience she will help the company to deliver a unique diagnostic technology to patients and society,“ says Elypta Chairman of the Board, Anders Ekblom.

Eva Pisa

Eva Pisa founded Sangtec Molecular Diagnostics in 2001 and led the company as CEO to profitability and divesture to Cepheid (now Danaher) in 2007. She later joined Roche Diagnostics where she between 2007 and 2020 held positions with increasing responsibilities. Under her tenure the cobas 6800/8800 was developed and launched. Pisa most recently served as a Senior Vice President and was responsible for Clinical Chemistry, Endocrinology and Custom Biotech (B2B) before retiring. She is currently a board member of several biotechnology companies. She holds a doctorate from the Karolinska Institute and a Masters in business from Heriot-Watt University.

“I am very much looking forward to working with the team at Elypta in the exciting field of early cancer detection. The team is working on a mass-spectrometer based detection platform where I see a great opportunity as the technology expands into routine use,” says Eva Pisa.

Photo of Eva Pisa: Elypta

Advertisement